Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...
Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective cut by The Goldman Sachs Group from $66.00 to $57.00 ...
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
4d
Fintel on MSNEvercore ISI Group Upgrades CRISPR Therapeutics (CRSP)Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results